JENNIFER CRISP: Open Payments
NPI 1134609696 · TRUMANN, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$453 in 18 payments from 10 companies in 2025. Trend: 2023 $329 · 2024 $315 · 2025 $453
Food & beverage: $453
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 1 | $96 |
| Biogen, Inc. | 4 | $86 |
| Astellas Pharma US Inc | 3 | $74 |
| MILLICENT US INC | 3 | $45 |
| Organogenesis Inc. | 1 | $33 |
| Organon LLC | 2 | $32 |
| Boston Scientific Corporation | 1 | $24 |
| Exeltis, USA Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
Products named: EVENITY, ZURZUVAE, Veozah, CYGNUS MATRIX, NEXPLANON, INTRAROSA, CDS - MCT/CEM Monitoring, SLYND.
Industry payments across AR — which companies pay providers there.
